Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Apellis Pharmaceuticals Inc

APLS
Current price
61.58 USD +7.71 USD (+14.31%)
Last closed 53.87 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 297 230 336 USD
Yield for 12 month +24.71 %
Week
Month
Year
APLS
21.11.2021 - 28.11.2021

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Analytics

WallStreet Target Price

71.19 USD

P/E ratio

Dividend Yield

Current Year

+75 422 000 USD

Last Year

+66 563 000 USD

Current Quarter

+99 182 000 USD

Last Quarter

+94 969 000 USD

Current Year

+69 786 000 USD

Last Year

+61 363 000 USD

Current Quarter

+76 772 000 USD

Last Quarter

+86 590 000 USD

Key Figures APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -594 960 000 USD
Operating Margin TTM -115.11 %
PE Ratio
Return On Assets TTM -44.1 %
PEG Ratio
Return On Equity TTM -224.59 %
Wall Street Target Price 71.19 USD
Revenue TTM 272 876 992 USD
Book Value 1.96 USD
Revenue Per Share TTM 2.35 USD
Dividend Share
Quarterly Revenue Growth YOY 400.5 %
Dividend Yield
Gross Profit TTM 69 786 000 USD
Earnings Share -5.23 USD
Diluted Eps TTM -5.23 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -222.09 %

Dividend Analytics APLS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 25.4594
Price Sales TTM 26.7418
Enterprise Value EBITDA -12.0771
Price Book MRQ 31.3863

Financials APLS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators APLS

For 52 weeks

19.83 USD 94.75 USD
50 Day MA 46.16 USD
Shares Short Prior Month 16 231 193
200 Day MA 60.75 USD
Short Ratio 8.36
Shares Short 16 137 939
Short Percent 15.85 %